The Mind: Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind?
作者信息
Reis Leonardo de Oliveira, Carter H Ballentine
机构信息
Department of Urology, Johns Hopkins Hospital, Baltimore, MD, USA.
Faculty of Medicine (Urology) Center for Life Sciences, Pontifical Catholic University of Campinas(PUC-Campinas) Campinas, SP, Brazil.
出版信息
Int Braz J Urol. 2015 Jan-Feb;41(1):10-4. doi: 10.1590/S1677-5538.IBJU.2015.01.03.
Abstract
摘要
相似文献
1
The Mind: Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind?
Int Braz J Urol. 2015 Jan-Feb;41(1):10-4. doi: 10.1590/S1677-5538.IBJU.2015.01.03.
2
Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind? - The Cancer.
Int Braz J Urol. 2015 Jan-Feb;41(1):5-9. doi: 10.1590/S1677-5538.IBJU.2015.01.02.
3
Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.
Eur Urol. 2012 Jul;62(1):55-63. doi: 10.1016/j.eururo.2012.03.006. Epub 2012 Mar 21.
4
5
New tests for prostate cancer.
J Natl Cancer Inst. 2013 Nov 20;105(22):1672-4. doi: 10.1093/jnci/djt344. Epub 2013 Nov 6.
6
Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
Eur Urol. 2010 Dec;58(6):836-7. doi: 10.1016/j.eururo.2010.09.003. Epub 2010 Sep 15.
7
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
J Urol. 2007 Dec;178(6):2260-7. doi: 10.1016/j.juro.2007.08.072. Epub 2007 Oct 15.
8
Prostate cancer: to treat or not to treat?
Johns Hopkins Med Lett Health After 50. 2013 Jan;24(12):1-2.
9
Expert panel advocates surveillance for men with low-risk prostate cancer.
JAMA. 2012 Jan 11;307(2):133. doi: 10.1001/jama.2011.1965.
10
Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Con.
J Urol. 2017 Nov;198(5):997-999. doi: 10.1016/j.juro.2017.08.088. Epub 2017 Sep 22.
引用本文的文献
1
Do rapid emotional thermometers correlate with multidimensional validated structured questionnaires in low-risk prostate cancer?
Int Urol Nephrol. 2020 Jun;52(6):1073-1078. doi: 10.1007/s11255-020-02399-w. Epub 2020 Feb 13.
2
T cells CD4+/CD8+ local immune modulation by prostate cancer hemi-cryoablation.
World J Urol. 2020 Mar;38(3):673-680. doi: 10.1007/s00345-019-02861-0. Epub 2019 Jul 1.
3
Prostate cancer "super-active surveillance" era opened by vascular targeted photodynamic therapy.
Res Rep Urol. 2019 May 29;11:157-163. doi: 10.2147/RRU.S178038. eCollection 2019.
4
Super active surveillance for low-risk prostate cancer | Opinion: Yes.
Int Braz J Urol. 2019 Mar-Apr;45(2):210-214. doi: 10.1590/S1677-5538.IBJU.2019.02.02.
本文引用的文献
1
Burden of focal cryoablation versus brachytherapy versus active surveillance in the treatment of very low-risk prostate cancer: a preliminary head-to-head comprehensive assessment.
Eur J Cancer Care (Engl). 2015 Nov;24(6):929-37. doi: 10.1111/ecc.12307. Epub 2015 Mar 5.
2
Gleason underestimation is predicted by prostate biopsy core length.
World J Urol. 2015 Jun;33(6):821-6. doi: 10.1007/s00345-014-1371-9. Epub 2014 Aug 2.
3
Characteristics and experiences of patients with localized prostate cancer who left an active surveillance program.
Patient. 2014;7(4):427-36. doi: 10.1007/s40271-014-0066-z.
4
Supporting prostate cancer focal therapy: a multidisciplinary International Consensus of Experts ("ICE").
Aging Male. 2014 Jun;17(2):66-71. doi: 10.3109/13685538.2014.895319. Epub 2014 Mar 6.
5
NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer.
NIH Consens State Sci Statements. 2011;28(1):1-27.
6
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy.
Clin Cancer Res. 2012 Oct 1;18(19):5471-8. doi: 10.1158/1078-0432.CCR-12-1502. Epub 2012 Sep 24.
7
Radical prostatectomy versus observation for localized prostate cancer.
N Engl J Med. 2012 Jul 19;367(3):203-13. doi: 10.1056/NEJMoa1113162.
8
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
Ann Intern Med. 2012 Jul 17;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459.
9
Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.
Eur Urol. 2012 Apr;61(4):851-4. doi: 10.1016/j.eururo.2012.01.023. Epub 2012 Jan 24.
10
Management of low (favourable)-risk prostate cancer.
BJU Int. 2011 Dec;108(11):1684-95. doi: 10.1111/j.1464-410X.2010.10489.x.
Zotero 插件